Fulvestrant (faslodex)

[MaNiCC]

Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. It is administered as a once-monthly injection.
Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.
Clinical uses
Fulvestrant is a Selective Estrogen Receptor Down-Regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

Fulvestrant
Identifiers
CAS number 129453-61-8
ATC code L02BA03
PubChem CID 104741
IUPHAR ligand ID 1015
DrugBank APRD00654

Chemical data
Formula C32H47F5O3S
Mol. mass 606.772 g/mol
Pharmacokinetic data
Protein binding 99%
Half-life 40 days

Therapeutic considerations
Pregnancy cat. D
Legal status Rx only
Routes Intramuscular injection